Salute e Benessere

HKBU develops Microfluidic Flow Cytomolecular Analyser to promote extensive…

Flow cytometers, based primarily on laser technology, are molecular testing equipment used to detect cellular characteristics. As cell samples pass through the equipment's channels, they sequentially move through a laser-illuminated area. Fluorescent markers attached to the samples will then emit fluorescence signals, which are detected and recorded by signal receivers. This allows the analysis of both the surface and interior of the cells, including various parameters related to cell…
PR Newswire
14/08/2025

Vitamin B12 Market Set to Surpass USD 444.47 Million by 2030, Driven by Rising…

For An In-Depth Breakdown of Market Trends, Forecasts, and Industry Segmentation, Download Free Sample of the Report Here: https://www.marknteladvisors.com/query/request-sample/global-vitamin-b12-market.html For An In-Depth Breakdown of Market Trends, Forecasts, and Industry Segmentation, Download Free Sample of the Report Here :https://www.marknteladvisors.com/query/request-sample/global-vitamin-b12-market.html Leading Companies in the Vitamin B12 Market: The competitive landscape...
PR Newswire
14/08/2025

MINISO Strengthens European Expansion and Retail Innovation with New Amsterdam…

With approximately 4,000 SKUs spanning plush toys, blind boxes, mini collectibles, and lifestyle accessories, the flagship is tailored for trend-savvy shoppers looking for the latest in creative, fun, and highly engaging products. Among these is a curated selection of MINISO's most popular collectible toy lines, including hit vinyl plush toys that have taken Gen Z and young adult shoppers by storm around the world with their fun emotional appeal and cultural relevance. To celebrate...
PR Newswire
14/08/2025

Implantica publishes Interim Report January - June 2025 (Q2)

Significant events in the second quarter of 2025 Significant events in the second quarter of 2025 Significant events after the end of the period Financial summary second quarter 2025 First six months Telephone conference Implantica will hold a teleconference on14 August 2025at 15:00 (CEST) withPeter Forsell(CEO), Andreas Öhrnberg (CFO), andNicole Pehrsson(Chief Corporate Affairs Officer). Please see the dial-in details below to join the conference: ...
PR Newswire
14/08/2025

Norgine completes acquisition of Theravia

With the transaction now complete, Norgine will begin a structured integration process to align operations, systems, and teams. "We are pleased about the successful closing of this acquisition as the addition of Theravia to our company further enhances our expertise in, and growing portfolio of rare disease medicines,"saidJanneke van der Kamp, Chief Executive Officer, Norgine. "This acquisition marks a critical step forward in our growth strategy, and with our strong focus on...
PR Newswire
14/08/2025

Shilpa Medicare's NorUDCA Makes History as First Approved NAFLD Therapy…

"Receiving approval for NorUDCA marks a transformational leap—not only for Shilpa Medicare but for millions silently suffering from liver disease. We are honored to be the first company globally to bring this innovative therapy to patients, reflecting our unwavering commitment to pioneering healthcare solutions and expanding access to life-changing treatments across India and beyond. We are excited to launch NorUDCA in India immediately and are actively pursuing approvals worldwide to…
PR Newswire
14/08/2025

Navamedic ASA: Financial report for the 2nd quarter and first half of 2025

"Having invested in various strategic growth initiatives over the last year, we are encouraged by the results in the second quarter of 2025. Excluding the Orion license fee last year, the 5.8 per cent revenue growth was positively impacted by Nordic tender wins for our antibiotics portfolio. Furthermore, several products, including Imdur® from our Prescription Drugs (RX) segment, have shown strong performance this quarter," said Kathrine Gamborg Andreassen, CEO of Navamedic…
PR Newswire
14/08/2025

Bioretec Ltd's Half-year report 2025: Strong support for future growth from a…

April–June 2025 in brief April–June 2025 in brief January–June 2025 in brief Key figures Key events in April–June 2025 Sarah van Hellenberg Hubar-Fisher, Interim CEO of Bioretec Ltd: The second quarter included the close of our successful funding round ofEUR 9 million, highlighting investors' confidence in our innovative product offering, market potential, and strategic direction. This funding round supports the needed investment in leadership resourcing for...
PR Newswire
14/08/2025

Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 14, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an exclusive license agreement with Venatorx Pharmaceuticals, Inc., to acquire the global rights to ceftibuten-ledaborbactam etzadroxil, a clinical phase 3-ready oral...
Nasdaq GlobeNewswire
14/08/2025

Kuros Biosciences Reports First Half of 2025 Results

Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences Reports First Half of 2025 ResultsFinancial HighlightsTotal Medical Device sales rose by 78% to USD 63.5 million in H1 2025 (H1 2024: USD 35.7 million)Direct MagnetOs™ sales increased by 77% to USD 62.7 million in H1 2025 (H1 2024: USD 35.4 million)The Group achieved its first-ever operating profit, reaching USD 3.5 million, compared to an operating loss of USD (0.2) million in H1 2024...
Nasdaq GlobeNewswire
14/08/2025

Zealand Pharma Announces Financial Results for the First Half of 2025

Company announcement – No. 18 / 2025 Zealand Pharma Announces Financial Results for the First Half of 2025 Petrelintide collaboration with Roche off to a strong start, while key leadership appointments and solid financial position enable exciting next chapter for Zealand Pharma. Collaboration and license agreement with Roche to co-develop and co-commercialize petrelintide as a future foundational therapy for weight management off to a strong start, with further insight and updates...
Nasdaq GlobeNewswire
14/08/2025

Press Release: Sanofi’s rilzabrutinib earns orphan designation in the EU for…

Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related diseaseData from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at EULAR 2025Additional orphan designation underscores Sanofi commitment to advancing new medicines in immune-mediated rare diseasesParis, August 14, 2025.The European Medicines Agency has granted orphan designation to rilzabrutinib, a reversible covalent Bruton’s tyrosine kinase (BTK)...
Nasdaq GlobeNewswire
14/08/2025

Alpha Global partners with LIO to redefine Mental Health Care in Australia

Jeremy Clare, Head of Product at Alpha Global, said: Jeremy Clare , Head of Product at Alpha Global, said: "We're incredibly excited to bring the second generation of mental health monitoring technology toAustraliawith the launch of LIO. This platform is a significant step forward in supporting clinicians with intelligent, contactless insights that enhance patient care and safety. It's a proud moment for us to introduce a solution purpose-built for mental health environments — one...
PR Newswire
14/08/2025

Global Digital Therapeutics Market Experiencing Rapid Growth at a CAGR of ~28%…

Digital Therapeutics Overview Digital Therapeutics Overview Digital therapeutics are evidence-based therapeutic interventions delivered through software programs to prevent, manage, or treat medical disorders and diseases. Unlike general wellness apps, digital therapeutics undergo rigorous clinical validation and regulatory review to demonstrate their efficacy, much like traditional pharmaceuticals. These interventions are often used in areas like mental health, chronic disease management...
PR Newswire
13/08/2025

Alvotech Reports Results for the First Six Months of 2025 and Provides a…

Strong performance driven by over 200% growth in product revenues year-on-year Best quarter in Alvotech’s history in terms of operating cash flowsContinued expansion of commercial partnerships for pipeline assetsAlvotech listed on Nasdaq Stockholm MarketConference call and live webcast on Thursday August 14, 2025, 8:00 am ET (12:00pm GMT) REYKJAVIK, Iceland, August 13, 2025 -Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the...
Nasdaq GlobeNewswire
13/08/2025

Defibrillator Market worth US$16.44 billion by 2030 with 6.5% CAGR |…

Browse in-depth TOC on "Defibrillator Market" Browse in-depth TOC on "Defibrillator Market" 337 - Tables 57 - Figures 296 - Pages By product,the defibrillators market is broadly segmented into implantable cardioverter defibrillators (ICDs) and external defibrillators. The implantable cardioverter defibrillators (ICDs) segment is anticipated to capture the largest global defibrillator market share by product in 2024. Timely intervention using implantable defibrillators...
PR Newswire
13/08/2025

SC Johnson Secures World Health Organization Policy Recommendation for…

Spatial repellents are tools that, when used, release an active ingredient which repels mosquitoes from a room, preventing mosquitoes from biting people and ultimately lessening the transmission of disease. They can be hung in semi-enclosed spaces, including homes and schools, and are about the size of a sheet of paper. They are easy to use, low-cost, long-lasting and effective. Spatial repellents are tools that, when used, release an active ingredient which repels mosquitoes from a room,...
PR Newswire
13/08/2025

Veterinary Infectious Disease Diagnostics Market worth US$4.22 billion by 2030…

The rising trend of pet ownership also contributes to market growth, as pet owners are increasingly investing in advanced veterinary care, including early disease detection. Supportive government initiatives and increased research and development spending by key industry players also play a vital role in driving the expansion of this market. The rising trend of pet ownership also contributes to market growth, as pet owners are increasingly investing in advanced veterinary care, including…
PR Newswire
13/08/2025

New Study Demonstrates Superiority of EggNest™ Complete Radiation Protection…

"From the beginning, Egg Medical has had three guiding principles: we need to protect the entire team from scatter radiation, we can't interfere with workflow or patient access, and the reduction in radiation exposure must be nearly complete. The study by Riley et al shows very clearly that the EggNest Complete system dramatically reduces radiation exposure for everyone in the room, and that the operator and assistant are almost completely protected. That is a marked improvement to safety…
PR Newswire
13/08/2025

On World Organ Donation Day KFSHRC Announces 10 Kidney Exchange Transplants…

This accomplishment reflects the hospital’s high clinical readiness, the seamless coordination of its multidisciplinary medical teams, and its advanced systems for managing donor-recipient matching, alongside its extensive experience in executing complex transplant procedures. All of these factors enable KFSHRC to carry out this type of exchange transplantation with precision and within an exceptionally short timeframe.Paired kidney transplantation is an innovative approach that matches...
Nasdaq GlobeNewswire
13/08/2025

Immatics Announces Second Quarter 2025 Financial Results and Business Update

Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: One-time infusion continues to show favorable tolerability as well as strong anti-tumor activity and durability in 33 heavily pretreated patients with metastatic melanoma in data from a Phase 1b trial presented at the 2025 ASCO Annual Meeting: 56% cORR, 12.1 months mDOR at 13.4 months mFU, 6.1 months mPFS and 15.9 months mOS Anzu-cel (IMA203) PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in...
Nasdaq GlobeNewswire
13/08/2025

ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate…

U.S. FDA Grants Fast Track Designation for PMN310 in Alzheimer’s Disease, enhancing program’s potential for priority reviewPRECISE-AD Phase 1b Trial in Alzheimer’s Disease Progressing on Schedule: Over 50% enrolled, no cases of ARIA and no patient dropouts to dateStrengthened Financial Position with $21.6 Million in Gross Proceeds Raised in July 2025 Cambridge, Massachusetts, Aug.13, 2025(GLOBE NEWSWIRE) --ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage...
Nasdaq GlobeNewswire
13/08/2025

Tilray Medical Forms Strategic Partnership in Italy to Broaden Access to Medical…

Tilray’s FL Group Teams Up with Molteni, a Major Pharmaceutical Firm Focused on Pain and Substance Dependence Therapies The partnership is designed to broaden the availability of Tilray Medical cannabis extracts for patients across Italy. Molteni will collaborate with FL Group by providing targeted education on medical cannabis therapies through Molteni’s comprehensive network of pharmaceutical, scientific, and medical professionals throughout Italy.“This partnership reflects our...
Nasdaq GlobeNewswire
13/08/2025

Adult Class II Malocclusion Cases Treated with Smartee S8-SGTB Published in JAO

The development of clear aligner technologies has made this possible. The Smartee S8-SGTB appliance combines the principles of conventional sagittal guidance Twin-Block with the convenience of a clear aligner system, offering a discreet, patient-friendly, and more accurate alternative for correcting Class II malocclusions with Smartee's digitalized solution. The development of clear aligner technologies has made this possible. The Smartee S8-SGTB appliance combines the principles of...
PR Newswire
13/08/2025
Altri  Comunicati